Table 2.
Rates and reasons for discontinuation
| Etanercept cohort | Adalimumab cohort | Tocilizumab cohort | Adalimumab versus etanercepta | Tocilizumab versus etanercepta | Tocilizumab versus adalimumaba | |
|---|---|---|---|---|---|---|
| n = 419 | n = 236 | n = 74 | OR (95% CI); p value | OR (95% CI); p value | OR (95% CI); p value | |
| Discontinuations, n (%) | 207 (49.4) | 142 (60.4) | 23 (31.1) | 1.57 (1.03; 2.41); 0.037 | 0.20 (0.09; 0.45); <0.001 | 0.13 (0.06; 0.29); <0.001 |
| Inefficacy, n (%) | 50 (11.9) | 52 (22.0) | 9 (12.2) | 1.65 (0.88; 3.08); 0.118 | 0.34 (0.11; 1.00); 0.050 | 0.20 (0.07; 0.60); 0.004 |
| Remission, n (%) | 54 (12.9) | 22 (9.3) | 2 (2.7) | 0.78 (0.43; 1.40); 0.404 | 0.12 (0.02; 0.79); 0.027 | 0.16 (0.02; 1.05); 0.056 |
| Intolerance, n (%) | 15 (3.6) | 15 (6.4) | 2 (2.7) | 2.28 (1.03; 5.04); 0.042 | 0.84 (0.18; 4.01); 0.826 | 0.37 (0.08; 1.79); 0.216 |
| Details | Hypersensitivity (5), uveitis (3), vasculitis (1), | Infections (4)b | Impetigo (1) | |||
| Lymphoma (1) | Hypersensitivity (3) | Neutropenia (1) | ||||
| Elevated transaminases (1), neuro-psychiatric (4)b | Pustulosis (1), neuro-psychiatric (5)b | 0.2 | 5 | |||
| Others*, n (%) | 88 (16.0) | 53 (22.4) | 10 (13.4) | 1.21 (0.74; 1.96); 0.443 | 0.27 (0.10; 0.72); 0.009 | 0.22 (0.08; 0.60); 0.003 |
aAnalyses weighted by an inverse probability of treatment estimated by a generalized propensity score. bInfections included pneumonia and soft tissue infections; Neuropsychiatric included headache, nausea, aggressiveness, anxiety, and vertigo. beta regression coefficient for continuous variables, CI confidence interval, OR odds ratio for categorical variable